Compass Pathways goes further in the red in 2024 as trial results loom

Green Market Report
By Adam JacksonFeb 27, 2025, 10:35 am124 ptsTrendingTop
Compass Pathways (NASDAQ: CMPS) deepened its financial losses to $155.1 million in 2024 as the company nears a big milestone for its experimental psilocybin therapy, with pivotal clinical trial results expected by midyear. The drug maker reported Thursday that its losses widened from $118.5 million in 2023,…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Verano misses on fourth-quarter revenue, posts wider annual loss 68

Verano Reports $879 Million in 2024 Revenue 67

Trulieve appoints marijuana MSO’s co-founder Pernell as new president 67

Ohio GOP senators advance bill to kill marijuana social equity, limit industry 67

Ayurcann posts 25% sales growth in second quarter, projects C$50M revenue in 2025 66

Trulieve Announces Appointment of Co-Founder Jason Pernell as President 66

North Dakota: House Members Advance Measure Reducing Marijuana Possession Penalties 64

Intellectual property of cannabis brand High Times is for sale again 64

About NewsBudz

NewsBudz is a marijuana and medical cannabis news app. The site delivers a daily feed of the latest cannabis news. We aggregate over 30 of the web's best sources for news about marijuana, hemp and legalization to keep you informed.

Stay on top of the latest news headlines, trends and developments worldwide around recreational and medical marijuana. Sit back and relax, while you read learn and share. On the web or your mobile device, NewsBudz is your cannabis news stream.